Chr Hansen   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Horsholm Denmark (1874)
Status: Acquired by Novonesis (2023)

Organization Overview

First Clinical Trial
2004
NCT00268164
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chr Hansen

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteriuria (Phase 1)

Candidiasis (Phase 1)

Candidiasis, Vulvovaginal (Phase 1)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Communicable Diseases (Phase 4)

Dental Caries (Phase 4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diarrhea (Phase 3)

Infections (Phase 4)

Respiration Disorders (Phase 3)

Respiratory Tract Diseases (Phase 3)

Rhinitis (Phase 3)

Ulcer (Phase 2)

Vaginitis (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 22